A significant new treatment for Eosinophilic Esophagitis (EoE) is EOHILIA (budesonide oral suspension), a corticosteroid developed specifically for this condition. This novel medication offers a unique approach to managing EoE in eligible patients.
Introducing EOHILIA: A Novel Approach to EoE Treatment
EOHILIA is a prescription medication designed to treat Eosinophilic Esophagitis. It represents a targeted advancement in EoE therapy, providing a corticosteroid formulation optimized for delivery to the esophageal lining.
Key Features and Benefits of EOHILIA
EOHILIA stands out due to its specific design and properties, making it an important option for those managing EoE:
- Type of Medication: It is a corticosteroid, known for its anti-inflammatory properties that help reduce the eosinophil-driven inflammation in the esophagus characteristic of EoE.
- Targeted Indication: EOHILIA is indicated for a 12-week treatment course in patients 11 years and older diagnosed with EoE.
- Unique Formulation: A key innovation of EOHILIA is its novel formulation of budesonide, which confers thixotropic properties. This means the suspension flows more freely when shaken (e.g., in its container) but becomes more viscous or thicker when swallowed.
How EOHILIA Works
The thixotropic property of EOHILIA is crucial to its effectiveness. When swallowed, the suspension thickens, allowing it to better coat the esophageal lining. This enhanced contact helps deliver the active ingredient, budesonide, directly to the inflamed tissues of the esophagus, where it can exert its anti-inflammatory effects more efficiently. This targeted delivery aims to reduce the eosinophil count and inflammation associated with EoE.
By directly addressing the inflammation in the esophagus, EOHILIA helps manage the symptoms of EoE, which can include difficulty swallowing and food impaction.
